Can streptomycin prevent the selection of isoniazid-resistant mutants in nude mice infected with M. tuberculosis?

C. Andrejak, S. Tyagi, E. Nuermberger, J. Grosset (Baltimore, United States Of America)

Source: Annual Congress 2011 - Translational models of disease
Session: Translational models of disease
Session type: Thematic Poster Session
Number: 856
Disease area: Respiratory infections

Congress or journal article abstractE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
C. Andrejak, S. Tyagi, E. Nuermberger, J. Grosset (Baltimore, United States Of America). Can streptomycin prevent the selection of isoniazid-resistant mutants in nude mice infected with M. tuberculosis?. Eur Respir J 2011; 38: Suppl. 55, 856

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Extensively drug – resistant tuberculosis: detection of a Gyr B mutant resistance
Source: Annual Congress 2008 - Difficult tuberculosis cases
Year: 2008


Estimation of susceptibility of multy-drug resistant strains of Mycobacterium tuberculosis (MTB) to chlorine containing disinfectants in experiment
Source: Annual Congress 2010 - Tuberculosis drug resistance
Year: 2010

Efficacy of anti-tuberculosis therapy with INH, RIF and Bedaquiline in mice with different genetic susceptibility to the infection
Source: International Congress 2019 – Tuberculosis: from basic science to patient care
Year: 2019

Relationship between rpoB mutations and minimum inhibitory concentrations of rifampicin in multi drug resistant strains of mycobacterium tuberculosis
Source: Annual Congress 2011 - Tuberculosis: from bench to bedside
Year: 2011

Induction of M. tuberculosis (MTB) drug resistance (DR) mutations in HIV-infected hosts and pathways of further spread of the evolutionary successful drug-resistant MTB clonal lines
Source: Virtual Congress 2020 – Multidrug-resistant tuberculosis
Year: 2020


Multi-drug-resistant tuberculosis: how is it produced, how should it be prevented, how may it be treated?
Source: Annual Congress 2004 - PG11 - Multiresistant tuberculosis and atypical mycobacterial disease
Year: 2004


Detection of mutations associated with isoniazid and rifampicin resistance in M. tuberculosis isolates from Kazakhstan
Source: Annual Congress 2010 - Emerging drug resistance in tuberculosis
Year: 2010

Evaluation of a molecular assay for detection of rifampin and isoniazid resistant mycobacterium tuberculosis in strains and clinical samples
Source: Annual Congress 2008 - Genetics, immunology and microbiology of tuberculosis
Year: 2008


Minimal inhibitory concentrations (MIC) of first line drugs in multidrug resistant strains of M. tuberculosis (MDR-TB)
Source: Annual Congress 2010 - Tuberculosis drug resistance
Year: 2010

Multi drug resistant (rifampicin + isoniazid) pulmonary tuberculosis – a challenge for a developing country specially co-infected with HIV
Source: Eur Respir J 2007; 30: Suppl. 51, 421s
Year: 2007

Relationship between exposure with drug resistant tuberculosis and developing new resistant cases
Source: Annual Congress 2009 - Treatment of tuberculosis at times of emerging drug resistance
Year: 2009


Susceptibility of Mycobacterium tuberculosis strains to fluoquinolones, obtained from chronic patients with multidrug resistant pulmonary tuberculosis
Source: Eur Respir J 2001; 18: Suppl. 33, 315s
Year: 2001

Rapid molecular detection of rifampicin and isoniazid resistance and identification of mutations in resistant genes of multi-drug resistant tuberculosis (MDR-TB) patients
Source: Annual Congress 2011 - Novel strategies for the diagnosis of tuberculosis
Year: 2011


In vitro and vivo study of isoxyl, a mycolic acid inhibitor for intermittent chemotherapy of multi drug resistant (MDR) strains of mycobacterium tuberculosis (M.tb)
Source: Eur Respir J 2006; 28: Suppl. 50, 587s
Year: 2006

Recommending prolonged bedaquiline use for the treatment of highly resistant strains of tuberculosis
Source: Eur Respir J, 50 (5) 1701552; 10.1183/13993003.01552-2017
Year: 2017



Treatment of resistant tuberculosis in patients having isolates resistant to multiple antituberculosis drugs
Source: Annual Congress 2010 - Prognosis of tuberculosis
Year: 2010

Therapeutic effect of adenoviral vector-mediated GM-CSF gene transfer in lung antimycobacterial immunity in M. bovis BCG infected mice
Source: International Congress 2016 – Rifampicin resistance, MDRTB, and new drug treatments
Year: 2016

Anti-TB efficacy of PBTZ169 in mice with different genetic susceptibility to infection
Source: Virtual Congress 2020 – Non-tuberculous mycobacteria and latent tuberculosis infection
Year: 2020


New inbred mouse strains for the studying M. tuberculosis – host interactions
Source: International Congress 2018 – Genetics in chronic pulmonary diseases
Year: 2018

The effect of bleomycin on the lungs of TGFβ1 transgenic mice
Source: Eur Respir J 2001; 18: Suppl. 33, 80s
Year: 2001